Envudeucitinib Phase 3 gains and Q1 2026 results for Alumis (NASDAQ: ALMS)
Rhea-AI Filing Summary
Alumis Inc. reported first quarter 2026 results and highlighted strong Phase 3 data for its oral TYK2 inhibitor envudeucitinib in moderate-to-severe plaque psoriasis. For the quarter ended March 31, 2026, total revenue was $1,741 (in thousands) compared with $17,389 (in thousands) a year earlier, with a net loss of $93,053 (in thousands) versus $98,963 (in thousands).
The Phase 3 psoriasis study showed robust skin clearance, with PASI 90 responses of 68.0% and 62.1% and PASI 100 responses of 41.0% and 39.5% at Week 24, along with improvements in quality of life and symptoms. Alumis plans to submit a New Drug Application for envudeucitinib in plaque psoriasis in the fourth quarter of 2026 and anticipates potentially pivotal Phase 2b topline data in systemic lupus erythematosus in the third quarter of 2026. Cash, cash equivalents and marketable securities contributed to total assets of $671,588 (in thousands) as of March 31, 2026.
Positive
- None.
Negative
- None.
8-K Event Classification
Key Figures
Key Terms
tyrosine kinase 2 (TYK2) inhibitor medical
New Drug Application regulatory
plaque psoriasis medical
systemic lupus erythematosus medical
forward-looking statements regulatory
Earnings Snapshot
FAQ
What were Alumis (ALMS) Q1 2026 revenues and net loss?
How strong were Alumis (ALMS) Phase 3 psoriasis results for envudeucitinib?
What regulatory milestones did Alumis (ALMS) outline for envudeucitinib?
What was Alumis (ALMS) cash and investment position at March 31, 2026?
How did Alumis (ALMS) research and development spending change in Q1 2026?
What is Alumis (ALMS) focusing on beyond plaque psoriasis?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
| | |||
(State or other jurisdiction |
| (Commission |
| (IRS Employer |
(Address of principal executive offices)
Registrant’s telephone number, including area code: (
N/A
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | | Trading | | Name of each exchange |
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 2.02 Results of Operations and Financial Condition.
On May 14, 2026, Alumis Inc. (the “Company”) issued a press release announcing, among other things, its financial results for the fiscal quarter ended March 31, 2026. A copy of the press release is attached hereto as Exhibit 99.1.
All of the information furnished in this Item 2.02 and Exhibit 99.1 of this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, and shall not be incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d)Exhibits.
Exhibit No. | | Description |
99.1 | Press Release, dated May 14, 2026. | |
104 | | Cover Page Interactive Data File (embedded within the Inline XBRL Document). |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Alumis Inc. | ||
By: | /s/ Martin Babler | |
Martin Babler | ||
President and Chief Executive Officer | ||
Dated: May 14, 2026
Exhibit 99.1
Alumis Reports First Quarter 2026 Financial Results and
Highlights Recent Achievements
– Late-breaking oral presentation of Phase 3 envudeucitinib data in moderate-to-severe plaque psoriasis (PsO) at the 2026 American Academy of Dermatology (AAD) Annual Meeting demonstrating early and robust improvements in skin clearance, quality of life, and symptoms –
– Data showed robust PASI responses by Week 16, with significant continued improvements by Week 24 in PASI 90 (68.0%, 62.1%) and PASI 100 (41.0%, 39.5%) –
– Data continue to underscore envudeucitinib’s potential as a leading oral therapy for PsO; plans to submit NDA in 4Q 2026 remain on track –
– Potentially pivotal Phase 2b topline data for envudeucitinib in systemic lupus erythematosus (SLE) anticipated 3Q 2026 –
SOUTH SAN FRANCISCO, Calif., May 14, 2026 – Alumis Inc. (Nasdaq: ALMS), a late-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases, today reported financial results for the quarter ended March 31, 2026, and highlighted recent achievements and upcoming milestones.
"Alumis delivered a focused and productive first quarter, building on the Phase 3 clinical validation of envudeucitinib in moderate-to-severe plaque psoriasis and reinforcing the differentiated potential of maximal TYK2 inhibition," said Martin Babler, President and Chief Executive Officer of Alumis. "Late-breaking Phase 3 data at the 2026 American Academy of Dermatology Annual Meeting demonstrated leading skin-clearance outcomes and meaningful improvements in patient-reported quality-of-life measures, supporting a compelling emerging profile for physicians and patients, if approved, and further strengthening our confidence in envudeucitinib’s potential to reshape the psoriasis treatment landscape."
Babler added, "We remain on track for our NDA submission in the fourth quarter of this year, as well as the potentially pivotal LUMUS Phase 2b topline readout in SLE in the third quarter. With continued progress across both indications, envudeucitinib is emerging as a potential ‘pipeline in a pill’, supporting expansion into additional immune-mediated diseases. We are evaluating further indications under a unified TYK2 franchise strategy and expect to share further updates later this year."
First Quarter 2026 and Recent Highlights
Envudeucitinib: a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in patients with moderate-to-severe plaque psoriasis
| ● | Late-breaking oral presentation of Phase 3 ONWARD1 and ONWARD2 envudeucitinib data at the 2026 American Academy of Dermatology (AAD) Annual Meeting (link to presentation) |
| o | Envudeucitinib achieved robust PASI responses by Week 16, with significant continued improvements by Week 24, including PASI 90 responses of 68.0% and 62.1% and PASI 100 responses of 41.0% and 39.5% |
| o | Quality-of-life improvements and itch relief emerged ahead of PASI 90 skin clearance, highlighting envudeucitinib’s early onset and broad clinical benefit |
| o | Clear or almost clear scalp psoriasis, a high-impact, difficult-to-treat area, emerged as early as Week 4 in more than 30% of patients, and was observed in approximately three out of four patients by Week 241 |
| o | Envudeucitinib demonstrated a favorable safety and tolerability profile consistent with the Phase 2 program |
| ● | Company management participated in a virtual key opinion leader (KOL) event following the AAD presentation featuring leading dermatology and psoriasis expert Dr. Andrew Blauvelt (link to the presentation and webcast replay: https://shorturl.at/A4Dh2) |
| ● | Narrative review published in peer-reviewed Dermatology and Therapy highlights envudeucitinib as a next-generation, oral, allosteric TYK2 inhibitor with strong molecular properties and favorable clinical efficacy and safety in psoriasis. The review synthesizes preclinical and clinical evidence demonstrating potent, sustained TYK2 inhibition and reinforces its potential across psoriasis and other immune-mediated diseases. (link to publication) |
Lonigutamab Update
| ● | Alumis has completed its strategic review of the lonigutamab program and decided to explore strategic alternatives for this asset. |
Anticipated 2026 Milestones
| ● | Envudeucitinib in Moderate-to-Severe Plaque Psoriasis |
| o | Long-term data - ONWARD3 topline data and Phase 2, two-year safety data (2H 2026) |
| o | NDA submission (4Q 2026) |
| ● | Envudeucitinib in SLE |
| o | Potentially pivotal Phase 2b SLE topline data (3Q 2026) |
| ● | TYK2 Franchise |
| o | Update on unified TYK2 franchise development strategy, including evaluation of additional indications (2Q 2026) |
| ● | Next clinical candidate (new target) |
| o | Initiate Phase 1 trial (2H 2026) |
1 Based on patients with baseline ss-PGA ≥3.
First Quarter 2026 Financial Results
| ● | As of March 31, 2026, Alumis had cash, cash equivalents and marketable securities of $569.5 million. |
| ● | Revenue included collaboration revenue of $1.7 million for the three months ended March 31, 2026, compared to license revenue of $17.4 million for the three months ended March 31, 2025, related to the collaboration and licensing agreement with Kaken Pharmaceutical Co., Ltd. |
| ● | Research and development expenses were $81.5 million for the three months ended March 31, 2026, compared to $96.6 million for the three months ended March 31, 2025. The decrease was primarily driven by lower contract research and clinical trial costs following completion of enrollment and reporting of positive topline results for the pivotal Phase 3 ONWARD1 and ONWARD2 clinical trials of envudeucitinib in patients with PsO in January 2026, partially offset by an increase in personnel-related expenses. |
| ● | General and administrative expenses were $18.6 million for the three months ended March 31, 2026, compared to $22.3 million for the three months ended March 31, 2025. The decrease was primarily attributable to transaction costs related to the merger with ACELYRIN, Inc. in the three months ended March 31, 2025, partially offset by an increase in personnel-related expenses. |
| ● | Net loss was $93.1 million for the three months ended March 31, 2026, compared to $99.0 million for the three months ended March 31, 2025. |
Financial Guidance
| ● | Based on the Company’s current operating plan, Alumis continues to anticipate that its existing cash, cash equivalents and marketable securities as of March 31, 2026 are expected to fund operating expenses and capital expenditure requirements into the fourth quarter of 2027. |
About Alumis
Alumis is a late-stage biopharmaceutical company developing next-generation targeted therapies with the potential to significantly improve patient health and outcomes across a range of immune-mediated diseases. Leveraging its proprietary data analytics platform and precision approach, Alumis is developing a pipeline of oral tyrosine kinase 2 inhibitors, consisting of envudeucitinib, formerly known as ESK-001, for the treatment of systemic immune-mediated disorders, such as moderate-to-severe plaque psoriasis and systemic lupus erythematosus, and A-005 with neuroinflammatory, neurodegenerative and peripheral immune-mediated disease indications under evaluation. For more information, visit www.alumis.com or follow us on LinkedIn or X.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of federal securities laws, including the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as "anticipates," "believes," "plans," "seeks," "will" and variations of these words or similar expressions that are intended to identify forward-looking statements. All statements, other than statements of historical facts, including without limitation those regarding the timing of the initiation of clinical trials, including a Phase 1 trial for the Company’s next clinical candidate, the timing of clinical data readouts in its ongoing clinical trials, including long-term and safety data, the timing of the Company’s planned NDA submission with the FDA for envudeucitinib in moderate-to-severe plaque psoriasis, the expected timing of the presentation of the Company’s TYK2 franchise strategy and the evaluation of additional indications, the potential for envudeucitinib to treat moderate-to-severe plaque psoriasis, the potential for envudeucitinib to reshape the psoriasis treatment landscape, systemic lupus erythematosus and other immune-mediated diseases, the Company’s plans to explore strategic alternatives for lonigutamab, any expectations regarding the safety, efficacy or tolerability of its drug candidates and statements regarding Alumis’ future plans and prospects, including development of its clinical pipeline and the commencement of additional clinical trials; cash runway; Alumis’ participation at upcoming conferences, and any assumptions underlying any of the foregoing, are forward-looking statements. Forward-looking statements in this press release are based on Alumis’ current expectations, estimates and projections as of the date of this release and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely and readers are cautioned that actual results, levels of activity, safety, efficacy, performance or events and circumstances could differ materially from those expressed or implied in Alumis’ forward-looking statements. Such risks and uncertainties include, without limitation, those related to Alumis’ ability to advance envudeucitinib or its other programs and to obtain regulatory approval of and ultimately commercialize Alumis’ clinical candidates, the timing, costs, and results of preclinical and clinical trials, Alumis’ ability to fund development activities and achieve development goals, Alumis’ ability to protect its intellectual property and other risks and uncertainties described in Alumis’ filings with the Securities and Exchange Commission (SEC) under the heading “Risk Factors” and elsewhere in such filings and reports, including any future reports Alumis may file with the SEC from time to time. Alumis explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.
ALUMIS INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(Unaudited)
| | Three Months Ended March 31, | ||||
(in thousands) | | 2026 | | 2025 | ||
Revenue: | | | | | | |
License revenue | | $ | — | | $ | 17,389 |
Collaboration revenue | | | 1,741 | | | — |
Total revenue | | | 1,741 | | | 17,389 |
Operating expenses: | | | | | | |
Research and development expenses | | | 81,540 | | | 96,622 |
General and administrative expenses | | | 18,610 | | | 22,295 |
Total operating expenses | |
| 100,150 | |
| 118,917 |
Loss from operations | |
| (98,409) | |
| (101,528) |
Other income (expense): | |
| | |
| |
Interest income | |
| 5,349 | | | 2,609 |
Other income (expenses), net | |
| 7 | | | (44) |
Total other income (expense), net | |
| 5,356 | |
| 2,565 |
Net loss | | $ | (93,053) | | $ | (98,963) |
Other comprehensive income (loss): | |
| | |
| |
Unrealized gain (loss) on marketable securities, net | |
| (655) | |
| (48) |
Total comprehensive loss | | $ | (93,708) | | $ | (99,011) |
ALUMIS INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)
| | March 31, | | December 31, | ||
(in thousands) |
| 2026 |
| 2025 | ||
Assets | | | | | | |
Current assets: | | | | | | |
Cash and cash equivalents |
| $ | 63,885 |
| $ | 89,670 |
Restricted cash | | | 86 | | | 82 |
Marketable securities, current | | | 459,058 | | | 218,831 |
Research and development prepaid expenses | | | 3,345 | | | 2,909 |
Other prepaid expenses and current assets | | | 6,033 | | | 6,740 |
Total current assets | | | 532,407 | | | 318,232 |
Restricted cash, non-current | | | 1,302 | | | 1,301 |
Marketable securities, non-current | | | 46,603 | | | — |
Property and equipment, net | | | 17,534 | | | 18,190 |
Intangible assets | | | 50,959 | | | 50,959 |
Operating lease right-of-use assets, net | | | 15,952 | | | 16,971 |
Other assets, non-current | | | 6,831 | | | 6,287 |
Total assets |
| $ | 671,588 |
| $ | 411,940 |
Liabilities and Stockholders’ Equity | | | | | | |
Current liabilities: | | | | | | |
Accounts payable |
| $ | 11,587 |
| $ | 10,106 |
Research and development accrued expenses | | | 35,959 | | | 34,781 |
Other accrued expenses and current liabilities | | | 12,588 | | | 22,303 |
Deferred revenue, current | | | 6,328 | | | 1,458 |
Operating lease liabilities, current | | | 4,442 | | | 4,670 |
Total current liabilities | | | 70,904 | | | 73,318 |
Operating lease liabilities, non-current | | | 31,222 | | | 32,244 |
Deferred tax liability | | | 2,140 | | | 2,140 |
Share repurchase liability | | | 94 | | | 123 |
Deferred revenue, non-current | | | — | | | 2,611 |
Other liabilities, non-current | | | 207 | | | 207 |
Total liabilities | | | 104,567 | | | 110,643 |
Stockholders’ equity: | | | | | | |
Preferred stock | | | — | | | — |
Common stock | | | 12 | | | 10 |
Additional paid-in capital | | | 1,562,405 | | | 1,202,975 |
Accumulated other comprehensive income (loss) | | | (467) | | | 188 |
Accumulated deficit | | | (994,929) | | | (901,876) |
Total stockholders’ equity | | | 567,021 | | | 301,297 |
Total liabilities and stockholders’ equity |
| $ | 671,588 |
| $ | 411,940 |
Alumis Contact Information
Teri Dahlman
Red House Communications
teri@redhousecomms.com